- Obesity Genes Mean Some Folks Must Exercise More for Same Results
- SCOTUS Appears Skeptical of Arguments to Curb Abortion Pill Access
- Sleep Troubles Can Raise Your Blood Pressure: Study
- ADHD Meds Tied to Heart Damage in Young Adult Users
- Could Regular Exercise Cure Your Insomnia? New Research Says Yes
- Black Men Less Likely to Receive Heart Transplants Than White Men or Women
- Could Deep Frying Foods Harm the Brain? Rat Study Suggests It Might
- Human Brains Are Getting Larger With Each Generation
- Animals Catch More Viruses From Us Than We Do From Them
- Young Adults With Migraine May Face Higher Stroke Risk
Zydelig Approved for Three Types of Blood Cancer
Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL), the FDA said Wednesday in a news release.
The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said.
The drug’s label will include a boxed warning that the medication could cause liver toxicity, diarrhea, high blood sugar, elevated liver enzymes, high blood triglycerides [a blood fat] and inflammation of the colon (colitis). Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash.
Zydelig is marketed by Gilead Sciences, based in Foster City, Calif.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.